About Johnson & Johnson Innovation – JJDC
Johnson & Johnson Innovation – JJDC is a venture capital firm founded in 1973. It is primarily based out of Cambridge, United States. As of Jun 2026, Johnson & Johnson Innovation – JJDC is an active investor, having invested in 130 companies, with 1 new investment in the last 12 months. It primarily invests in Series C round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Seed round of Trimtech Therapeutics Overall, Johnson & Johnson Innovation – JJDC portfolio has seen 1 unicorn, 17 IPOs and 54 acquisitions including key companies like 23andMe, Epicor and PAIGE. A lot of funds co-invest with Johnson & Johnson Innovation – JJDC, with names like Novartis Venture Fund sharing a substantial percentage of its portfolio. Johnson & Johnson Innovation – JJDC has team of 12 people including 3 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 9 more
Portfolio Acquisitions
Portfolio Unicorns
Deals in last 12 months
Johnson & Johnson Innovation – JJDC's List of Top Investments
Johnson & Johnson Innovation – JJDC has a portfolio of 130 companies, one of which is a Unicorn. Their most notable investments are in Pronota and NeuroPace.Their portfolio spans across United States, Israel, United Kingdom and 8 more locations. They have invested in Life Sciences, HealthTech, High Tech and 8 other sectors, across stages such as Series B, Series A and 9 more. Here is the list of top investments by Johnson & Johnson Innovation – JJDC:
1. 23andMe
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits. The platform provides a study regarding an individual's ancestry, genealogy, and inherited traits. The company also markets its data is categorized and searchable form to researchers and scientists.
Key facts about 23andMe
- Founded Year: 2006
- Location: Sunnyvale (United States)
- Annual Revenue: $100M - $500M as on Mar 31, 2025
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $944M
- Employee Count: 555 as on May 31, 2026
- Investors: Fidelity Investments, SeedFord Partners and 34 Others
- Latest Funding Round: Post IPO, Nov 03, 2023, $*****
- Highlight: Acquired
2. Epicor
Cloud-based enterprise resource planning software for the automotive industry. The company caters to the manufacturing, distribution, retail, hospitality, and services industries. It provides customer relationship management, supply chain management, human capital management, and enterprise retail software solutions. It also provides POS solutions to help manufacturers and retailers perform operations including order management, payments, returns, and more.
Key facts about Epicor
- Founded Year: 1972
- Location: Austin (United States)
- Stage: Acquired
- Total Funding till date: $229M
- Employee Count: 6,221 as on May 31, 2026
- Investors: Apax, ACE & Company and 10 Others
- Latest Funding Round: Series D, Aug 13, 2024, $*****
- Highlight: Acquired
3. Welldoc
WellDoc’s flagship product, BlueStar, is a Mobile Prescription Therapy that enables patients to self-manage their diabetes through real-time motivational, behavioral, and educational coaching. Personalized coaching is provided using patented algorithms and real-time analysis of patient diabetes data. BlueStar requires a prescription from a licensed healthcare provider and can be dispensed and reimbursed through a pharmacy.
Key facts about Welldoc
- Founded Year: 2005
- Location: Columbia (United States)
- Stage: Series B
- Total Funding till date: $82.1M
- Employee Count: 365 as on May 31, 2026
- Investors: Merck Global Health Innovation Fund, Hudson River Capital Partners and 13 Others
- Latest Funding Round: Series B, Mar 01, 2016, $*****
- Highlight: Editors' Pick
4. PAIGE
Developer of AI applications and foundation models for cancer diagnostics. The company provides tissue-based AI-assisted applications to support cancer detection, subtyping, and molecular biomarker discovery. It offers technology to accelerate research and development of computational pathology applications. The company’s co-pilot is designed to streamline pathology workflows and unlock precision medicine.
Key facts about PAIGE
- Founded Year: 2018
- Location: New York City (United States)
- Stage: Acquired
- Total Funding till date: $241M
- Employee Count: 63 as on Sep 26, 2025
- Investors: Breyer Capital, Casdin Capital and 9 Others
- Latest Funding Round: Series C, Jan 11, 2023, $*****
- Highlight: Acquired
Developer of therapeutic solutions for treating multiple diseases. The company specializes in developing DARPin that is designed with ankyrin repeat proteins-based therapies for the treatment of severe or life-threatening diseases with an initial focus on oncology and ophthalmology. MP0250 is their most advanced oncology candidate and can be used for the treatment of solid tumors and hematological malignancies.
Key facts about Molecular Partners
- Founded Year: 2004
- Location: Zurich (Switzerland)
- Stage: Public
- Total Funding till date: $59.9M
- Employee Count: 148 as on May 31, 2026
- Investors: Endeavour Vision, Index Ventures and 4 Others
- Latest Funding Round: Post IPO, Jul 2020, $*****
- Highlight: Public
Johnson & Johnson Innovation – JJDC's Year-on-Year Investment Trends
Johnson & Johnson Innovation – JJDC has invested in 130 companies over the last 27 years, with an average of 4 new investments annually in the last 10 years. In 2025, it made 2 investments, while as of Jun 2026, it has made 2 investments in this year. Its most recent first time investment was in Trimtech Therapeutics and most recent follow-on round was in TRexBio.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 1 | 2 |
2025 | 2 | 0 | 2 |
2024 | 7 | 2 | 9 |
2023 | 1 | 2 | 3 |
2022 | 2 | 0 | 2 |
2021 | 3 | 3 | 6 |
2020 | 7 | 2 | 9 |
2019 | 5 | 1 | 6 |
2018 | 8 | 1 | 9 |
2017 | 3 | 5 | 8 |
Johnson & Johnson Innovation – JJDC's Investments by Stage
Johnson & Johnson Innovation – JJDC has made 33 investments in Series B stage with an average round size of $40.7M, 29 investments in Series A stage with an average round size of $23.8M and 28 investments in Series C stage with an average round size of $34.8M.Stage of entry | No. of Investments |
|---|---|
Series B | 33 |
Series A | 29 |
Series C | 28 |
Series D | 15 |
Seed | 5 |
Others | 10 |
Note: We have considered here, only first round of investments
Johnson & Johnson Innovation – JJDC's Investments by Sector
Johnson & Johnson Innovation – JJDC has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Enterprise Applications and Internet of Things - Industry Applications. Notably, it has invested in 115 Tech companies, 94 Enterprise (B2B) companies, 30 Tech hardware companies and at least 27 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 103 |
High Tech | 17 |
HealthTech | 15 |
Enterprise Applications | 8 |
Internet of Things - Industry Applications | 7 |
Others | 27 |
Note: We have considered here, only first round of investments
Johnson & Johnson Innovation – JJDC's Investments by Geography
Johnson & Johnson Innovation – JJDC has made most investments in United States (92), followed by Israel where it has made 9 investments.Country | No. of Investments |
|---|---|
United States | 92 |
Israel | 9 |
United Kingdom | 7 |
Switzerland | 3 |
Belgium | 2 |
Others | 7 |
Note: We have considered here, only first round of investments
Johnson & Johnson Innovation – JJDC's recent investments
Johnson & Johnson Innovation – JJDC has made 2 investments in 2026 so far - Trimtech Therapeutics and TRexBio.Here are the most recent investments by Johnson & Johnson Innovation – JJDC:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 23, 2026 | United Kingdom | Seed | 8761 | [+8] | |
Jan 27, 2026 | United States | Series B | 3582 | ||
May 13, 2025 | United States | Series A | 4133 | ||
Feb 11, 2025 | United States | Series A | 6548 | [+2] | |
Dec 09, 2024 | Netherlands | Series B | 8157 | [+2] |
Unicorns in Johnson & Johnson Innovation – JJDC's Portfolio
Johnson & Johnson Innovation – JJDC has 1 unicorn in its portfolio - Carbon. The most recent unicorn in their portfolio is Carbon which became a unicorn in 2019, 1 years after Johnson & Johnson Innovation – JJDC first invested in it.Here is a list of unicorns in Johnson & Johnson Innovation – JJDC's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
69 | Provider of three-dimensional printing services using design software and advanced materials | 2013 | Redwood City | Series E | uyfqggq |
IPOs and Publicly Listed companies in Johnson & Johnson Innovation – JJDC's Portfolio
17 of Johnson & Johnson Innovation – JJDC's portfolio companies have become public. CVRx got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jun 2021 at marketcap of $126M and NeuroPace got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $390M.Here are Johnson & Johnson Innovation – JJDC's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 30, 2021 | May 09, 2007 | Series D | 3231 | |
Apr 22, 2021 | Aug 16, 2011 | Series C | 8792 | |
Aug 02, 2019 | Feb 20, 2019 | Series B | 2432 | |
Oct 23, 2018 | Mar 10, 2015 | Series C | 3051 | |
May 04, 2018 | May 15, 2014 | Series E | 5272 |
Acquired companies in Johnson & Johnson Innovation – JJDC's Portfolio
54 companies from Johnson & Johnson Innovation – JJDC's portfolio have been acquired. The most recent acquisition was Merus in Dec 2025 by Genmab for $*****.Here are Johnson & Johnson Innovation – JJDC's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 12, 2025 | Oct 03, 2013 | Series B | 8842 | |
Dec 05, 2025 | Sep 04, 2024 | Series B | 4528 | |
Sep 03, 2025 | Aug 14, 2020 | Series B | 5424 | |
Aug 22, 2025 | Jan 14, 2021 | Series C | 3914 | |
Jul 01, 2025 | Mar 05, 2024 | Series B | 8765 |
_1559123136606.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Team profile of Johnson & Johnson Innovation – JJDC
Johnson & Johnson Innovation – JJDC has a team of 12 members including 3 Partners and 9 Principals located in United States, Netherlands and 1 more location. Johnson & Johnson Innovation – JJDC's team does not sit on the board of any company as of now.Here is a list of top team members in Johnson & Johnson Innovation – JJDC:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Philadelphia | - | - | |
Partner | New Brunswick | - | - | |
Partner | Amsterdam | - | ||
Principal | Amsterdam | - | - | |
Principal | Antwerp | binx health, Intercytex and 1 more | - | |
Principal | San Francisco | - | ||
Principal | San Diego | - | ||
Principal | Irvine | - | - | |
Principal | New Brunswick | - | - | |
Principal | Cambridge | - | ||
Principal | Cambridge | - | - |
Co-investors of Johnson & Johnson Innovation – JJDC
Over the past 27 years, 841 investors have co-invested in Johnson & Johnson Innovation – JJDC's portfolio companies. This includes funds and angels.
- Invested before Johnson & Johnson Innovation – JJDC: Johnson & Johnson Innovation, New Enterprise Associates and 302 others have invested in rounds before Johnson & Johnson Innovation – JJDC. There are 13 companies where Johnson & Johnson Innovation has invested before Johnson & Johnson Innovation – JJDC and 10 companies where New Enterprise Associates has invested before Johnson & Johnson Innovation – JJDC.
- Top Co-investors of Johnson & Johnson Innovation – JJDC: 256 investors entered a company along with Johnson & Johnson Innovation – JJDC. These include investors like Novartis Venture Fund (6 companies).
- Invested after Johnson & Johnson Innovation – JJDC: A total of 281 investors have invested in Johnson & Johnson Innovation – JJDC's portfolio after their investments. Top Investors include Johnson & Johnson Innovation (14 companies), Medtronic (6 companies) and Orbimed (5 companies).
Recent News related to Johnson & Johnson Innovation – JJDC
•
•
•
•
Datavant Raises $40M in Series B FinancingFinSMEs•Oct 09, 2020•Datavant, Transformation Capital, Cigna Ventures, Roivant Sciences and 3 others
•
Aetion Raises Further $19M; Closes $82M Series B RoundFinSMEs•Aug 26, 2020•Aetion, Johnson & Johnson Innovation, Greenspring Associates, EDBI and 11 others
•
Vor Biopharma Closes $110 Million Series B FinancingBusiness Wire•Jul 07, 2020•RA Capital Management, Vor Biopharma, Fidelity Investments, and 8 others
•
Cue Health closes $100M to validate its connected molecular testing platformMobiHealthNews•Jun 10, 2020•ACME, Johnson & Johnson Innovation – JJDC, Foresite Capital, Decheng Capital and 3 others
•
Gatt Technologies Raises €10.5M in Series B FundingFinSMEs•May 18, 2020•GATT Technologies BV, Oost NL, Johnson & Johnson, Johnson & Johnson Innovation – JJDC and 1 other
•
RefleXion Raises $100 Million for Cancer Treatment CommercializationBusiness Wire•Apr 16, 2020•RefleXion, TPG, The Rise Fund, KCK Group and 12 others
•
